362 related articles for article (PubMed ID: 23376850)
21. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
[TBL] [Abstract][Full Text] [Related]
22. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
23. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
[TBL] [Abstract][Full Text] [Related]
24. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
De Lorenzo C; Troise F; Cafaro V; D'Alessio G
Br J Cancer; 2007 Nov; 97(10):1354-60. PubMed ID: 17923870
[TBL] [Abstract][Full Text] [Related]
25. A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.
Zhou M; Wang X; Xia J; Cheng Y; Xiao L; Bei Y; Tang J; Huang Y; Xiang Q; Huang S
Int J Nanomedicine; 2020; 15():3087-3098. PubMed ID: 32431503
[TBL] [Abstract][Full Text] [Related]
26. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
[TBL] [Abstract][Full Text] [Related]
27. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
[TBL] [Abstract][Full Text] [Related]
28. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
[TBL] [Abstract][Full Text] [Related]
29. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
[TBL] [Abstract][Full Text] [Related]
30. Genetically encoded immunophotosensitizer 4D5scFv-miniSOG is a highly selective agent for targeted photokilling of tumor cells in vitro.
Mironova KE; Proshkina GM; Ryabova AV; Stremovskiy OA; Lukyanov SA; Petrov RV; Deyev SM
Theranostics; 2013; 3(11):831-40. PubMed ID: 24312153
[TBL] [Abstract][Full Text] [Related]
31. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
[TBL] [Abstract][Full Text] [Related]
32. A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.
Zdobnova T; Sokolova E; Stremovskiy O; Karpenko D; Telford W; Turchin I; Balalaeva I; Deyev S
Oncotarget; 2015 Oct; 6(31):30919-28. PubMed ID: 26436696
[TBL] [Abstract][Full Text] [Related]
33. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin).
Büchler P; Reber HA; Büchler MC; Roth MA; Büchler MW; Friess H; Isacoff WH; Hines OJ
J Gastrointest Surg; 2001; 5(2):139-46. PubMed ID: 11331475
[TBL] [Abstract][Full Text] [Related]
34. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
[TBL] [Abstract][Full Text] [Related]
35. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
36. Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.
Kornberger P; Skerra A
MAbs; 2014; 6(2):354-66. PubMed ID: 24492291
[TBL] [Abstract][Full Text] [Related]
37. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Rosenblum MG; Marks JW; Cheung LH
Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
39. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
[TBL] [Abstract][Full Text] [Related]
40. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
